Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 226Breast Neoplasms 223Prostatic Neoplasms 163Multiple Myeloma 147Neoplasms 130Leukemia, Myeloid, Acute 117Colorectal Neoplasms 117Lung Neoplasms 112Neoplasm Metastasis 95Squamous Cell Carcinoma of Head and Neck 90Carcinoma, Hepatocellular 88Melanoma 83Lymphoma 81Triple Negative Breast Neoplasms 74Pancreatic Neoplasms 73Ovarian Neoplasms 72Sarcoma 66Lymphoma, Large B-Cell, Diffuse 63Carcinoma, Renal Cell 63Brain Neoplasms 62Recurrence 58Head and Neck Neoplasms 57Stomach Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Leukemia, Lymphocytic, Chronic, B-Cell 53Urinary Bladder Neoplasms 52Hematologic Neoplasms 52Lymphoma, Non-Hodgkin 51Small Cell Lung Carcinoma 50Endometrial Neoplasms 47

Interventions

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ventricular Dysfunction, Left × 90 days × Clear all
NCT07572175 2026-05-07

SPARTACUS

Icahn School of Medicine at Mount Sinai

Phase 2 Not yet recruiting
60 enrolled
Lymphoid

Lymphoma, Ventricular Dysfunction, Left, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡